|
Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Clinical research trials and Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer. Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer  Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
For Condition: stage 4 colon cancer,Quality of Life,adenocarcinoma of the rectum,recurrent rectal cancer,adenocarcinoma of the colon,Stage 4 rectal cancer,recurrent colon cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Jonsson Comprehensive Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known whether combination chemotherapy will be more effective with or without SU5416 in treating metastatic colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without SU5416 in treating patients who have metastatic colorectal cancer.
Details: OBJECTIVES: I. Compare the survival of patients with previously untreated metastatic colorectal cancer treated with fluorouracil, leucovorin calcium, and irinotecan with or without SU5416. II. Compare the antitumor efficacy of these regimens in these patients. III. Evaluate the additional measures of clinical benefit in patients treated with these regimens. IV. Determine the relative safety profile of these regimens in these patients. V. Assess quality of life of patients treated with these regimens. PROTOCOL OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to ECOG performance status (0 vs 1), baseline lactate dehydrogenase (normal vs elevated), and treatment regimen. Patients are randomized to 1 of 2 treatment arms by 2 different regimens (Saltz vs de Gramont). Regimen I (Saltz): Arm IA: Patients receive SU5416 IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, 25, 29, 32, 36, and 39. Patients also receive irinotecan IV over 30-90 minutes, leucovorin calcium IV over 5-10 minutes, and fluorouracil IV over 5-10 minutes on days 1, 8, 15, and 22. Arm IIA: Patients receive irinotecan, leucovorin calcium, and fluorouracil as in arm I. Treatment in both arms repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Regimen II (de Gramont): Arm IB: Patients receive SU5416 as in arm IA. Patients also receive irinotecan IV over 30-90 minutes on days 1, 15, and 29 and leucovorin calcium IV over 2 hours and fluorouracil IV over 2 hours on days 1, 2, 15, 16, 29, and 30. Arm IIB: Patients receive irinotecan, leucovorin calcium, and fluorouracil as in arm IB. Treatment in both arms repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, at the beginning of each course, and then at the end of treatment. Patients are followed at 1 month and then every 2 months for 4 years. PROJECTED ACCRUAL: A total of 1,270 patients (635 per treatment arm) will be accrued for this study within 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed adenocarcinoma of the colon or rectum; Newly diagnosed or recurrent disease - Measurable or evaluable metastatic disease that is previously untreated - No known brain or leptomeningeal metastases --Prior/Concurrent Therapy-- - Biologic therapy: At least 6 months since prior adjuvant antibody therapy, immunotherapy, gene therapy, vaccine therapy, or cytokine therapy; No prior systemic biologic therapy for metastatic disease, including antibody therapy, immunotherapy, gene therapy, vaccine therapy, cytokine therapy, or angiogenesis inhibitors (e.g., SU5416, matrix metalloprotease inhibitors, thalidomide, anti-VEGF/Flk-1 monoclonal antibody); No concurrent antibody therapy, immunotherapy, gene therapy, vaccine therapy, or angiogenesis inhibitors; No concurrent sargramostim (GM-CSF) - Chemotherapy: At least 6 months since prior adjuvant chemotherapy (e.g., fluorouracil, leucovorin calcium, levamisole, irinotecan, oxaliplatin, capecitabine, fluorouracil-uracil, or other cytotoxic agents); No prior systemic chemotherapy for metastatic disease; No prior intra-arterial cytotoxic chemotherapy for metastatic disease; No other concurrent chemotherapy - Endocrine therapy: No concurrent anticancer hormonal therapy - Radiotherapy: At least 6 months since prior adjuvant radioimmunotherapy or radiotherapy and recovered; No concurrent radiotherapy - Surgery: Recovered from prior surgery - Other: At least 6 months since other prior adjuvant therapy; No other prior systemic anticancer therapy for metastatic disease; No other concurrent anticancer therapy; No other concurrent experimental drugs; No concurrent participation in another clinical trial --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-1 - Life expectancy: Not specified - Hematopoietic: Absolute neutrophil count at least 1,500/mm3; Platelet count at least 100,000/mm3; Hemoglobin at least 8.0 g/dL - Hepatic: Bilirubin no greater than 1.8 times upper limit of normal (ULN); SGOT no greater than 5 times ULN; Alkaline phosphatase no greater than 5 times ULN; Lactate dehydrogenase no greater than 5 times ULN - Renal: Creatinine no greater than 1.5 times ULN - Cardiovascular: No myocardial infarction within the past 6 months; No ongoing unstable angina; No symptomatic congestive heart failure; No serious uncontrolled cardiac dysrhythmia; No stroke within the past 6 months - Gastrointestinal: No active inflammatory bowel disease; No significant bowel obstruction; No chronic diarrhea grade 2 or greater - Other: HIV negative; No AIDS-related illness; No known allergy to Cremaphor-containing products, irinotecan, fluorouracil, or to both warfarin (or similar oral anticoagulants) and low-molecular weight heparin; No other malignancy within the past 5 years except nonmelanoma skin cancer; No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LeeRosen, Study Chair, Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Additional Information:
Study ID Numbers: CDR0000068766; SUGEN-SU5416.035,NCI-G01-1980,UCLA-001003701
Study Start Date: December 2000
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00021281
Other Recurrent Colon Cancer Studies:
1. R115777 in Treating Patients With Advanced Colorectal Cancer
2. Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer
3. NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer
4. Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer
5. Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Related Studies:
Other recurrent colon cancer Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
|
|
|
|
|
|
|
|
